Recombinant adeno-associated vectors for targeted treatment

A method of treating a disease or disorder in a subject, comprising administering a vector comprising one or more therapeutic nucleotide sequences selected from the following:

• a) for muscle disease or disorders and for antibody genes or other vaccine treatments administered to the subject via the muscle, the vector selected from the group of AAVHSC7, AAVHSC13, AAVHSC15, and AAVHSC17;
• b) for heart and lung disease or disorders, the vector selected from the group of AAVHSC13, AAVHSC15, and AAVHSC17;
• c) for liver or neurological diseases or disorders, vector AAVHSC15;
• d) for conditions treated by engrafting stem cells, vector AAVHSC17;
• e) for conditions treated by transducing B cell progenitors, vector AAVHSC5;
• f) for conditions treated by transducing myeloid and erythroid progenitors, vector AAVHSC12;
• and
• g) for lymph node, kidney, spleen, cartilage and bone disease or disorders, the vector selected from the group of the vector selected from the group of AAVHSC7, AAVHSC13, AAVHSC15, and AAVHSC17;
• wherein the vector transduces the target cell or tissue and the therapeutic nucleotide sequences treat the disease or disorder.